[HTML][HTML] The emerging role of PPAR-alpha in breast cancer
Z Qian, L Chen, J Liu, Y Jiang, Y Zhang - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Breast cancer has been confirmed to have lipid disorders in the tumour microenvironment.
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated …
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated …
Targeting ion channels for cancer treatment: current progress and future challenges
AL Capatina, D Lagos, WJ Brackenbury - Targets of Cancer Diagnosis and …, 2020 - Springer
Ion channels are key regulators of cancer cell pathophysiology. They contribute to a variety
of processes such as maintenance of cellular osmolarity and membrane potential, motility …
of processes such as maintenance of cellular osmolarity and membrane potential, motility …
Apigenin and Luteolin Attenuate the Breaching of MDA-MB231 Breast Cancer Spheroids Through the Lymph Endothelial Barrier in Vitro
J Hong, A Fristiohady, CH Nguyen… - Frontiers in …, 2018 - frontiersin.org
Flavonoids, present in fruits, vegetables and traditional medicinal plants, show anticancer
effects in experimental systems and are reportedly non-toxic. This is a favorable property for …
effects in experimental systems and are reportedly non-toxic. This is a favorable property for …
Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro
Y Majeed, R Upadhyay, S Alhousseiny, T Taha… - Scientific reports, 2019 - nature.com
Angiosarcomas are highly aggressive tumors of endothelial origin, which carry a poor
prognosis. Fenofibrate is a hypolipidemic drug, which acts by activating the transcription …
prognosis. Fenofibrate is a hypolipidemic drug, which acts by activating the transcription …
Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro
S Holzner, S Brenner, AG Atanasov, D Senfter… - Food and Chemical …, 2018 - Elsevier
Mechanisms how colorectal cancer (CRC) cells penetrate blood micro-vessel endothelia
and metastasise is poorly understood. To study blood endothelial cell (BEC) barrier …
and metastasise is poorly understood. To study blood endothelial cell (BEC) barrier …
Resistance to antiangiogenic treatments: a review
T Koltai, SJ Reshkin, RA Cardone - Antiangiogenic Drugs as …, 2022 - Elsevier
Angiogenesis (blood vessel formation) is essential for tissue growth in both normal
development and physiology and in some diseases such as inflammation and cancer …
development and physiology and in some diseases such as inflammation and cancer …
[HTML][HTML] Genome-wide RNA-sequencing dataset reveals the prognostic value and potential molecular mechanisms of lncRNA in non-homologous end joining …
LM Shang, XW Liao, GZ Zhu, KT Huang, CY Han… - Journal of …, 2020 - ncbi.nlm.nih.gov
Objective: Our current study is to explore the prognostic value and molecular mechanisms
underlying the role of lncRNA in non-homologous end joining pathway 1 (LINP1) in early …
underlying the role of lncRNA in non-homologous end joining pathway 1 (LINP1) in early …
12 (S)-HETE induces lymph endothelial cell retraction in vitro by upregulation of SOX18
A Fristiohady, D Milovanovic… - International …, 2018 - spandidos-publications.com
Metastasising breast cancer cells communicate with adjacent lymph endothelia, intravasate
and disseminate through lymphatic routes, colonise lymph nodes and finally metastasize to …
and disseminate through lymphatic routes, colonise lymph nodes and finally metastasize to …
12 (S)-HETE induces lymph endothelial cell retraction in vitro by upregulation of SOX18
D Martin - International Journal of Oncology, 2018 - ingentaconnect.com
Metastasising breast cancer cells communicate with adjacent lymph endothelia, intravasate
and disseminate through lymphatic routes, colonise lymph nodes and finally metastasize to …
and disseminate through lymphatic routes, colonise lymph nodes and finally metastasize to …